- Home
- DALN vs BLUE Comparison
DALN vs BLUE Comparison
Compare DALN & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- BLUE
- Stock Information
- Founded
- DALN 1954
- BLUE 1992
- Country
- DALN United States
- BLUE United States
- Employees
- DALN N/A
- BLUE N/A
- Industry
- DALN Newspapers/Magazines
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DALN Consumer Discretionary
- BLUE Health Care
- Exchange
- DALN Nasdaq
- BLUE Nasdaq
- Market Cap
- DALN 38.1M
- BLUE 36.9M
- IPO Year
- DALN 2008
- BLUE 2013
- Fundamental
- Price
- DALN $4.32
- BLUE $4.97
- Analyst Decision
- DALN
- BLUE Hold
- Analyst Count
- DALN 0
- BLUE 7
- Target Price
- DALN N/A
- BLUE $44.60
- AVG Volume (30 Days)
- DALN 17.8K
- BLUE 1.1M
- Earning Date
- DALN 07-29-2025
- BLUE 05-14-2025
- Dividend Yield
- DALN N/A
- BLUE N/A
- EPS Growth
- DALN N/A
- BLUE N/A
- EPS
- DALN 5.55
- BLUE N/A
- Revenue
- DALN $123,414,000.00
- BLUE $103,946,000.00
- Revenue This Year
- DALN N/A
- BLUE $205.45
- Revenue Next Year
- DALN N/A
- BLUE $3.74
- P/E Ratio
- DALN $0.78
- BLUE N/A
- Revenue Growth
- DALN N/A
- BLUE 127.51
- 52 Week Low
- DALN $2.98
- BLUE $3.20
- 52 Week High
- DALN $7.86
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- DALN 45.38
- BLUE 62.82
- Support Level
- DALN $4.19
- BLUE $4.40
- Resistance Level
- DALN $4.64
- BLUE $5.01
- Average True Range (ATR)
- DALN 0.27
- BLUE 0.11
- MACD
- DALN 0.02
- BLUE 0.06
- Stochastic Oscillator
- DALN 47.54
- BLUE 96.72
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.